XXXX : Profile and Predictors of Survival Outcomes.

@entity1 @entity1820 @entity3 @entity420 @entity1349
UNASSIGNED: @entity420 is rare. We aimed to evaluate survival outcome and prognostic factors for survival in @entity1 with @entity420 in recent years, marked by advancement in chemotherapy for @entity1820 . All @entity1 treated for @entity420 at our institution between January 2000 and July 2013 were reviewed. Thirty-nine @entity1 were identified: 27 operative @entity1 [21(53.8%) curative and 6 (15.4%) palliative operations] and 12 nonoperative @entity1 [primary systemic chemotherapy, 4 (10.3%), palliative radiotherapy, 1 (2.6%), and no treatment, 7 (17.9%)]. Curative resections included 13 pancreaticoduodenectomies and eight segmental resections. Median @entity1349 ( @entity1349 ) for entire cohort was 14.4 months. Median @entity1349 and one-, three-, and five-year @entity1349 were operative group (41.4 months; 79.1%, 50.6%, and 10.6%, respectively); nonoperative group (7.4 months; 25.0%, 8.3%, and 0%, respectively); curative surgery (45.4 months; 92.9%, 62.5%, and 16.7%, respectively) and palliative surgery (5.4 months; 33.3%, 16.7%, and 0%, respectively). Female gender (P = 0.04), curative resection (P = 0.03), nodal @entity3 (P = 0.047) and advanced T stage (P = 0.047) were predictive of @entity1349 . Two factors were independently predictive of @entity1349 -female gender and curative resection. Overall survival still hinges on curative resection. This favors early detection. Adjuvant treatment modalities such as chemotherapy and radiation require further investigation.
